Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modulation of alpha synuclein expression

a technology of alpha synuclein and modulation, which is applied in the direction of muscular disorders, organic chemistry, drug compositions, etc., can solve the problems of lack of acceptable options for treating such neurodegenerative disorders

Active Publication Date: 2014-01-02
IONIS PHARMA INC
View PDF6 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent provides methods, compounds, and compositions for reducing the expression of alpha-synuclein mRNA and protein, which are associated with various neurodegenerative diseases such as Parkinson's Disease, dementia, and Alzheimer's Disease. The invention offers the potential to prevent, treat, and ameliorate these diseases by targeting the expression of alpha-synuclein. The techniques can be applied in a time-dependent or dose-dependent manner, and can involve the use of nucleic acids, proteins, antibodies, or small molecules. The patent also emphasizes the importance of risk factors and causes associated with the development of these diseases, which can be addressed through targeted inhibition of alpha-synuclein expression.

Problems solved by technology

There is a currently a lack of acceptable options for treating such neurodegenerative disorders.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modulation of alpha synuclein expression
  • Modulation of alpha synuclein expression
  • Modulation of alpha synuclein expression

Examples

Experimental program
Comparison scheme
Effect test

example 1

Antisense Inhibition of Human Alpha-Synuclein (SNCA) in HuVEC Cells

[0287]Antisense oligonucleotides targeted to an SNCA nucleic acid were tested for their effects on SNCA mRNA in vitro. Cultured HuVEC cells at a density of 5,000 cells per well were transfected using LipofectAMINE2000® reagent with 10 nM antisense oligonucleotide. After a treatment period of approximately 24 hours, RNA was isolated from the cells and SNCA mRNA levels were measured by quantitative real time PCR using the human primer probe set RTS2621 (forward sequence ACGAACCTGAAGCCTAAGAAATATCT, designated herein as SEQ ID NO: 8; reverse sequence GAGCACTTGTACAGGATGGAACAT, designated herein as SEQ ID NO: 9, probe sequence TGCTCCCAGTTTCTTGAGATCTGCTGACA, designated herein as SEQ ID NO: 10). SNCA mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN. Results are presented as percent inhibition of SNCA, relative to untreated control cells.

[0288]The chimeric antisense oligonucleotides in Tables...

example 2

Dose-Dependent Antisense Inhibition of Human SNCA in HuVEC Cells

[0294]Eleven gapmers, exhibiting over 84 percent or greater in vitro inhibition of human SNCA in the study described in Example 1, were tested at various doses in HuVEC cells. Cells were plated at a density of 6,000 cells per well and transfected using LipofectAMINE2000® reagent with 0.08 nM, 0.25 nM, 0.74 nM, 2.22 nM, 6.67 nM, and 20.00 nM concentrations of antisense oligonucleotide, as specified in Table 4. After a treatment period of approximately 16 hours, RNA was isolated from the cells and SNCA mRNA levels were measured by quantitative real-time PCR. Human SNCA primer probe set RTS2621 (described herein above in Example 1) was used to measure mRNA levels. SNCA mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN. Results are presented as percent inhibition of SNCA, relative to untreated control cells. As illustrated in Table 4, SNCA mRNA levels were reduced in a dose-dependent manner ...

example 3

Dose-Dependent Antisense Inhibition of Human SNCA in SH-SY5Y Cells

[0295]Gapmers were selected from the study described in Example 2 and tested at various doses in SH-SY5Y cells. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 5 μM, 10 μM, and 20 μM concentrations of antisense oligonucleotide, as specified in Table 5. After a treatment period of approximately 16 hours, RNA was isolated from the cells and SNCA mRNA levels were measured by quantitative real-time PCR. Human SNCA primer probe set RTS2620 (forward sequence GGTGCTTCCCTTTCACTGAAGT, designated herein as SEQ ID NO: 89; reverse sequence ACATCGTAGATTGAAGCCACAAAA, designated herein as SEQ ID NO: 90, probe sequence AATACATGGTAGCAGGGTCTTTGTGTGCTGTG, designated herein as SEQ ID NO: 91) was used to measure mRNA levels. SNCA mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN. Results are presented as percent inhibition of SNCA, relative to untreated co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.

Description

SEQUENCE LISTING[0001]The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BIOL0139WOSEQ.txt created Nov. 17, 2011, which is 170 Kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.FIELD OF THE INVENTION[0002]Embodiments of the present invention provide methods, compounds, and compositions for inhibiting expression of alpha-synuclein mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate neurodegenerative diseases, including, Parkinson's disease, dementia, multiple system atrophy, and Alzheimer's disease.BACKGROUND OF THE INVENTION[0003]Alpha-synuclein (also known as α-synuclein, SNCA, and a-SYN) is a small, highly charged 140-amino acid residue protein, predominantly expressed in central nervous system (CNS) neurons, where it is localized at presynaptic ter...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/113
CPCC12N15/113C12N2310/11C12N2310/315C12N2310/323C12N2310/3231C12N2310/3341C12N2310/341C12N2310/346A61P21/00A61P25/00A61P25/02A61P25/16A61P25/28A61P43/00C12N2310/321C12N2310/3525
Inventor BENNETT, C. FRANKFREIER, SUSAN M.MALLAJOSYULA, JYOTHI
Owner IONIS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com